Cargando…

Obstetrician/gynecologists’ HPV vaccination recommendations among women and girls 26 and younger

BACKGROUND: Obstetrician/gynecologists (OB/GYNs) are well poised to vaccinate girls and young women against HPV, however little is known about if and how they recommend the HPV vaccine. This study aims to understand factors associated with strong and frequent HPV vaccine recommendations among OB/GYN...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Luke P., Rodriguez, Natalia M., Head, Katharine J., Zimet, Gregory D., Kasting, Monica L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935521/
https://www.ncbi.nlm.nih.gov/pubmed/35321213
http://dx.doi.org/10.1016/j.pmedr.2022.101772
Descripción
Sumario:BACKGROUND: Obstetrician/gynecologists (OB/GYNs) are well poised to vaccinate girls and young women against HPV, however little is known about if and how they recommend the HPV vaccine. This study aims to understand factors associated with strong and frequent HPV vaccine recommendations among OB/GYNs for patients 26 years and younger. METHODS: 224 practicing U.S. OB/GYNs were surveyed for how strongly and frequently they recommend the HPV vaccine to patients 26 and younger. Provider beliefs, knowledge, and preferences surrounding the vaccine, as well as clinic and patient-level variables were examined as covariates. We then examined the relationships using multivariable logistic regression analyses. RESULTS: Of the 224 respondents, 205 were included in the analysis, with 57% (n = 116) reporting strongly and frequently recommending the HPV vaccination to eligible patients 26 and younger. The regression showed two provider beliefs and two clinic-level attributes to be strongly associated with strong and frequent recommendations. Being a strong and frequent recommender was positively associated with believing other gynecologists frequently recommend the vaccine (aOR 24.33 95%CI[2.56–231.14]) and believing that 50% or more of their patients are interested in receiving the vaccine (aOR 2.77 95%CI[1.25–6.13]). The clinic-level attributes were having the vaccine stocked (aOR 2.66 95%CI[1.02–6.93]) and suburban (aOR 3.31 95%CI[1.07–10.19]) or urban (aOR 3.54 95%CI[1.07–11.76]) location versus rural. CONCLUSIONS: These findings suggest that OB/GYN peer support and educating OB/GYN about patients’ interest in HPV vaccination may improve HPV vaccination. This work can inform clinic-level interventions including stocking the vaccine and focusing improvement efforts on rural clinics.